A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Odanacatib (Primary)
- Indications Bone cancer; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 05 Jan 2012 Actual initiation date changed from Feb 2010 to Dec 2009 as reported by ClinicalTrials.gov.
- 24 May 2010 Actual patient number (44) added as reported by ClinicalTrials.gov.